1. BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB‐3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM). (June 2017) Authors: Trotman, J.; Opat, S.; Marlton, P.; Gottlieb, D.; Simpson, D.; Cull, G.; Ritchie, D.; Verner, E.; Ratnasingam, S.; Anderson, M.; Wood, P.; Wang, L.; Xue, L.; Hedrick, E.; Huang, J.; Hilger, J.; Seymour, J.F.; Roberts, A.W.; Tam, C.S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. HIGH OVERALL RESPONSE RATE WITH THE BTK INHIBITOR BGB‐3111 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: AN UPDATE ON SAFETY AND ACTIVITY. (June 2017) Authors: Seymour, J.F.; Opat, S.; Cull, G.; Trotman, J.; Gottlieb, D.; Simpson, D.; Marlton, P.; Anderson, M.; Ku, M.; Ritchie, D.S.; Ratnasingam, S.; Augustson, B.; Kim, W.; Wang, L.; Xue, L.; Hilger, J.; Huang, J.; Hedrick, E.; Roberts, A.W.; Tam, C.S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAFETY AND ACTIVITY OF THE HIGHLY SPECIFIC BTK INHIBITOR, BGB‐3111 PLUS OBINUTUZUMAB IN PATIENTS (PTS) WITH FOLLICULAR LYMPHOMA (FL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). (June 2017) Authors: Tam, C.S.; Quach, H.; Nicol, A.; Badoux, X.; Rose, H.; Prince, H.; Leahy, M.F.; Eek, R.; Wickham, N.; Patil, S.; Huang, J.; Zhang, X.; Wang, L.; Hedrick, E.; Novotny, W.; Flinn, I. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗